Laatste update :
08/05/2024
Protonpompremmer   Esomeprazole sodium  
Injecteerbaar geneesmiddel
Stabiliteit in oplossing Stabiliteit in mengsels Factoren die de stabiliteit beïnvloeden Verenigbaarheden Toedieningswijze Literatuur Pdf
   Molecuulstructuur  

Merknamen in verschillende landen   Merknamen in verschillende landen     

Handelsnamen zijn slechts een indicatie; de samenstelling van hulpstoffen kan per land variëren afhankelijk van de fabrikant

Adptor Mexico
Axagon Italië
Axiago Zweden
Cativa Zweden
Cronopep Colombia, Peru
Eliprot Ecuador
Emune Ecuador
Epral Chili
Esio Ecuador
Esmonat Indië, Turkije
Esoblok Turkije
Esofax Ecuador
Esolium Peru
Esomep Zwitserland
Esomeprazol Chili, Colombia, Ecuador, Roemenië, Spanje
Esomeprazole USA
Esopral Italië, Zweden
Esopran Peru
Esoton Plus Peru
Esoz Colombia, Indië
Ezole Peru
Gletop Venezuela
Inexium Frankrijk
Milenium Ecuador
Nexiam België, Luxemburg
Nexium Argentinië, Chili, Colombia, Duitsland, Ecuador, Egypte, Griekenland, Groot Britannië, Ierland, IJsland, Italië, Maleisië, Mexico, Noorwegen, Portugal, Roemenië, Saudi-Arabië, Spanje, Turkije, USA, Venezuela, Verenigde Arabische Emiraten, Zweden, Zwitserland
Redica Zweden
Refexxin Zweden
Literatuur   Injecteerbaar geneesmiddel   Literatuur : Esomeprazole sodium  
Type Publicatie
1506 Artikel Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D.
Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units.
EJHP 2015 ;22:107-112.
1508 Artikel Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
2262 Artikel Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Artikel Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2270 Artikel Kupiec TC, Aloumanis V, Ben M, Trissel LA, Chan P, Patterson J.
Physical and chemical stability of esomeprazole sodium solutions.
Ann Pharmacotherapy 2008 ; 42, 9: 1247-1251.
2284 Fabrikant Esomeprazole sodium (Nexium IV®) – Summary of Product Characteristics
Astra Zenaca 2007
2311 Artikel Kambia N.K, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C.
Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
J Clin Pharm Ther 2009 ; 34: 25-31.
3249 Artikel Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Artikel Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332 Fabrikant Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3372 Artikel Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3429 Artikel Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S.
Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration
Am J Health-Syst Pharm 2015 ; 72:483-486
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3879 Artikel Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E.
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948 Artikel Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
4055 Artikel Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Artikel Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433 Artikel Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4465 Artikel Foushee A, Meredith P, Fox Laura, Wilder A.
Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4528 Artikel Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4650 Fabrikant Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4801 Artikel Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:

  Mentions Légales